Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | PNMT | P11086 | 6/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465997 | 0.94 | PNMT (0.47) | DRD2DRD3PNMTADRA2AADRA2B | |
| SCHEMBL20889994 | 0.87 | ITGB3 (0.31) | ASIC3PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL21118921 | 0.86 | ASIC3 (0.49) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL4565700 | 0.82 | ASIC3 (0.55) | ASIC3DRD2DRD3PNMTCD44 | |
| Hydrochloric Acid SCHEMBL1265678 | 0.80 | ASIC3 (0.53) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL22543786 | 0.79 | PNMT (0.49) | DRD2DRD3PNMTADRA2AADRA2B | |
| SCHEMBL3243076 | 0.79 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL3055999 | 0.79 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL18717400 | 0.79 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL3247113 | 0.79 | ASIC3 (0.51) | ASIC3DRD2DRD3PNMTCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | ASIC3 1844/4885DRD2 327/4885DRD3 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.